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Summary of findings {#CD011526-sec1-0001}
===================

Summary of findings for the main comparisonSmectite compared to control for acute infectious diarrhoea in children**Smectite compared to control for acute infectious diarrhoea in childrenPatient or population:** acute infectious diarrhoea in children **Setting:** hospital and outpatients **Intervention:** smectite **Comparison:** control**OutcomesAnticipated absolute effects\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)Comments (compared with control)Risk with controlRisk with smectite**Duration of diarrhoea assessed with: clinical and parental assessment, measured in total hours Follow‐up: mean 1 weekThe mean duration of diarrhoea ranged from 32.6 to 118.92 hoursMD 24.38 hours fewer (30.91 fewer to 17.85 fewer)‐2209 (14 RCTs)⊕⊕⊝⊝ LOW^1,2^Smectite may reduce the duration of diarrhoeaClinical resolution at day 3 assessed with: clinical assessment by parents and clinicians Follow‐up: mean 3 daysStudy populationRR 2.10 (1.30 to 3.39)312 (5 RCTs)⊕⊕⊝⊝ LOW^3,4^Smectite may increase the resolution of diarrhoea by the third day342 per 1000718 per 1000 (445 to 1000)Stool frequency assessed with: clinical assessment as number of depositions per day Follow‐up: mean 1 weekThe mean stool frequency was 0 depositions per dayMD 1.33 depositions per day fewer (2.28 fewer to 0.38 fewer)‐954 (3 RCTs)⊕⊝⊝⊝ VERY LOW^5,6,7^We are uncertain whether or not smectite reduces stool frequencyStool output assessed with: grams of stool output per kg of body weight in a 72‐hour period Follow‐up: mean 1 weekThe mean stool output ranged from 90.7 to 118.8 g/kgMD 11.37 g/kg fewer (21.94 fewer to 0.79 fewer)‐634 (3 RCTs)⊕⊕⊝⊝ LOW^7,8^Smectite may decrease stool outputNeed for hospitalization Follow‐up: mean 1 weekStudy populationRR 0.93 (0.75 to 1.15)885 (2 RCTs)⊕⊕⊝⊝ LOW^6,9^Smectite may make little or no difference in the need for hospitalization85 per 100079 per 1000 (64 to 98)Need for intravenous access for rehydration Follow‐up: mean 1 weekStudy populationRR 0.77 (0.54 to 1.11)81 (1 RCT)⊕⊕⊕⊝ MODERATE^9^Smectite probably makes little or no difference in the need for intravenoous access676 per 1000520 per 1000 (365 to 750)Adverse events -- constipation Follow‐up: mean 1 weekStudy populationRR 4.71 (0.56 to 39.19)128 (2 RCTs)⊕⊕⊝⊝ LOW^3,9^Smectite may make little or no difference in the appeareance of adverse events0 per 10000 per 1000 (0 to 0)Death‐‐‐‐‐There were no deaths in the included studiesSerious adverse events‐‐‐‐‐There were no serious side effects in the included studies\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).\
**Abbreviations: CI:** confidence interval; **MD:** mean difference; **RCT:** randomized controlled trial; **RR:** risk ratio**GRADE Working Group grades of evidence** **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^2]

Background {#CD011526-sec1-0002}
==========

Description of the condition {#CD011526-sec2-0001}
----------------------------

Acute diarrhoea is defined as the passage of unusually loose or watery stools, usually at least three times in a 24‐hour period, for less than 14 days ([@CD011526-bbs2-0032]; [@CD011526-bbs2-0043]; [@CD011526-bbs2-0044]). Incidence of acute diarrhoea in children under five years of age is approximately two to three episodes per child per year ([@CD011526-bbs2-0042]). The aetiology is usually infectious, and is usually transmitted by faecal‐oral route, or by contaminated water or food. Although most cases of acute diarrhoea are self limited, the most common complication is dehydration where children are at higher risk compared to adults. The objective of treatment in many countries is to relieve symptoms and avoid complications. In low‐ and middle‐income countries there are additional concerns to prevent dehydration and prevent the illness contributing to malnutrition. Therapeutic options for the latter objective include probiotics ([@CD011526-bbs2-0024]), zinc ([@CD011526-bbs2-0034]), lactose‐free formula ([@CD011526-bbs2-0037]), antibiotics, and antidiarrhoeal agents such as loperamide, racecadotril, and smectite.

Description of the intervention {#CD011526-sec2-0002}
-------------------------------

Smectite is a medicinal clay commonly prescribed to reduce stool output in people with diarrhoea. A survey conducted in 29 European countries with a response rate of 34% found that 22% of physicians (9% in Western European countries and 41% in Eastern European countries) would give smectite as an adjuvant treatment to children with gastroenteritis ([@CD011526-bbs2-0039]). In France, the use of smectite by private paediatricians may be as high as 84% ([@CD011526-bbs2-0041]). Another survey, conducted in Prague, Czech Republic, found that 45.7% of children with acute diarrhoea received smectite ([@CD011526-bbs2-0033]). A survey carried out in 20 hospitals in two Chinese provinces found that smectite was prescribed to 59.3% of adults with acute infectious diarrhoea ([@CD011526-bbs2-0029]).

How the intervention might work {#CD011526-sec2-0003}
-------------------------------

Dioctahedral smectite, or diosmectite, is a natural clay formed from sheets of aluminium and magnesium silicate. Its proposed mechanism of action differs from other antidiarrhoeal agents such as loperamide, which is an opioid‐receptor agonist, and racecadotril, which acts as an enkephalinase inhibitor. Three possible mechanisms of action of smectite against diarrhoea have been proposed: an anti‐inflammatory activity, alteration of the gut mucus barrier to reduce penetration of toxins, and adsorptive properties. These mechanisms have been replicated mainly in vitro and in animal models ([@CD011526-bbs2-0026]). In theory, these mechanisms would reduce stool output in children, thereby providing symptomatic relief and possibly preventing dehydration.

Why it is important to do this review {#CD011526-sec2-0004}
-------------------------------------

In many countries, symptomatic relief of diarrhoea is important to the public. Smectite is one such option for providing this relief. Two previous systematic reviews including 13 randomized controlled trials published between 1986 and 2013 provide evidence that smectite reduces the frequency and duration of diarrhoea in children ([@CD011526-bbs2-0025]; [@CD011526-bbs2-0040]). The only reported adverse event was constipation. Since acute diarrhoea is usually a self limited illness, provided the person is properly hydrated, it is important to assess the efficacy and safety of adjuvant therapies such as smectite. With the publication of recent trials, there was a need to update the evidence on this topic.

Objectives {#CD011526-sec1-0003}
==========

To assess the effects of smectite for treating acute infectious diarrhoea in children.

Methods {#CD011526-sec1-0004}
=======

Criteria for considering studies for this review {#CD011526-sec2-0005}
------------------------------------------------

### Types of studies {#CD011526-sec3-0001}

Randomized and quasi‐randomized trials comparing children with acute diarrhoea treated with smectite against a control group.

### Types of participants {#CD011526-sec3-0002}

We included trials evaluating children, aged one month to 18 years old, with clinically defined diarrhoea of less than 14 days duration, presumed to be caused by an infectious agent. We excluded studies with other causes of diarrhoea, such as chronic or antibiotic‐associated diarrhoea.

### Types of interventions {#CD011526-sec3-0003}

We included trials assessing oral smectite against a control group, either placebo or no smectite. We did not exclude trials that administered other interventions, such as probiotics or zinc, provided that the intervention and control arms were treated identically.

### Types of outcome measures {#CD011526-sec3-0004}

#### Primary outcomes {#CD011526-sec4-0001}

Duration of diarrhoea, measured in hours.Clinical resolution at day 3 after starting treatment.

#### Secondary outcomes {#CD011526-sec4-0002}

Stool frequency, measured as number of depositions per day, on day 3 after starting treatment.Stool output, measured in g or mL/kg per day.Need for hospitalization.Need for intravenous access for rehydration.Death (from any cause or diarrhoea‐related).Adverse events:serious adverse events (life‐threatening events).other adverse events (for example, constipation, vomiting, among others).

Search methods for identification of studies {#CD011526-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD011526-sec3-0005}

We searched the following databases using the search terms and strategy described in [Appendix 1](#CD011526-sec2-0016){ref-type="app"}: Cochrane Infectious Diseases Group Specialized Register (27 June 2017); Cochrane Central Register of Controlled Trials (CENTRAL) (27 June 2017), published in the Cochrane Library (2017, Issue 5); MEDLINE (Pubmed; 1946 to 27 June 2017); Embase (Ovid; 1974 to 27 June 2017); and LILACS (Latin American and Caribbean Health Sciences Literature) (1982 to 27 June 2017). We also searched the metaRegister of Controlled Trials ([mRCT](mRCT)) (27 June 2017) and the World Health Organization International Clinical Trials Registry Platform ([WHO ICTRP](WHO ICTRP)) (27 June 2017) using 'smectite\' and 'diosmectite\' as search terms ([Appendix 1](#CD011526-sec2-0016){ref-type="app"}).

### Searching other resources {#CD011526-sec3-0006}

#### Conference proceedings {#CD011526-sec4-0003}

We searched the following conference proceedings of the last two years (2014 to 2016) for relevant abstracts.

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).Infectious Diseases Society of America (IDSA) conferences.International Congress on Infectious Diseases (ICID) from the International Society for Infectious Diseases (ISID).

#### Researchers and organizations {#CD011526-sec4-0004}

We contacted researchers, authors of included trials, other experts in the field of infectious diseases, and pharmaceutical companies that manufacture smectite.

#### Reference lists {#CD011526-sec4-0005}

We also checked the reference lists of all studies identified by the above methods.

Data collection and analysis {#CD011526-sec2-0007}
----------------------------

### Selection of studies {#CD011526-sec3-0007}

Two review authors (GP and CC) independently screened the search results to identify potentially relevant trials and retrieved the full‐text articles of these trials. GP and CC independently applied the inclusion criteria using an eligibility form, resolving any differences by discussing them with a third review author (VP or IF). We scrutinized the trial reports to ensure that multiple publications from the same trial were included only once. We listed the excluded studies and the reasons for their exclusion in the '[Characteristics of excluded studies](#CD011526-sec2-0020){ref-type="sec"}\' section. Finally, when we were unsure whether a trial should be included because further information was needed, we attempted to contact the trial authors for clarification and allocated the trial to the 'Studies awaiting classification\' section. We have presented an adapted PRISMA flowchart showing study selection ([@CD011526-bbs2-0036]).

### Data extraction and management {#CD011526-sec3-0008}

Two review authors (GP and CC) independently extracted prespecified characteristics of each trial using a standardized, piloted data extraction form. We attempted to contact trial authors in cases of unclear or missing data. We extracted the following data.

The numbers of randomized and analysed participants in each treatment group for each outcome.The mean and standard deviation (SD) for each treatment group for continuous outcomes, and the number of participants with the event for each treatment group for dichotomous outcomes. If these values were not explicitly presented, we attempted to transform data where possible from available numbers such as 95% confidence intervals (CIs), standard errors, range or test statistics (that is, t, F, Z scores, P values, etc.). We obtained the SD from 95% CIs in one study according to the guidelines in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD011526-bbs2-0028]). We imputed SDs for studies that did not present any measure of data dispersion. We extracted information from figures in three trials that presented the results in this format and did not provide numerical values for measures of dispersion ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]), using the Plot Digitizer open source software ([@CD011526-bbs2-0031]). Two trials presented the information using median and 95% CI and provided a Kaplan‐Meier curve with the data for both intervention and control group ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]). We applied the Hozo and colleagues approach to calculate the best estimation of mean and SD ([@CD011526-bbs2-0030]).

### Assessment of risk of bias in included studies {#CD011526-sec3-0009}

Two review authors (GP and CC) independently assessed the risk of bias of the included studies, resolving any disagreements by discussion with a third review author (VP or IF). We attempted to contact trial authors regarding unclear or unspecified information. We used the Cochrane 'Risk of bias\' assessment tool, which includes the following domains ([@CD011526-bbs2-0028]).

Sequence generation: describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.Allocation concealment: describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.Blinding (masking) of participants, personnel, and outcome assessors: describe all measures used, if any, to mask trial participants, personnel, and outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended masking was effective.Incomplete outcome data: describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition or exclusions where reported, and any re‐inclusions in analyses performed by the review authors.Selective outcome reporting: state how the possibility of selective outcome reporting was examined by the review authors and what was found.Other sources of bias: state any important concerns about bias not addressed in the other domains in the tool.

We assessed the risk of bias for each component using 'yes\', 'no\', or 'unclear\' to indicate a low, high, or unclear risk of bias, respectively. We have presented the 'Risk of bias\' assessment in a 'Risk of bias\' graph and the 'Risk of bias\' tables.

#### Certainty of the evidence {#CD011526-sec4-0006}

We have presented the certainty of the evidence according to the GRADE approach. Two review authors (GP and CC) independently rated the certainty of the evidence for each outcome. Since we included randomized controlled trials, which are considered as high certainty, review authors could downgrade the body of evidence depending on five criteria: limitations, inconsistency, indirectness, imprecision, and publication bias. Evidence could be upgraded if a large effect size was found, if there was a dose‐response association, or if trial authors considered plausible confounding factors. We have presented a summary of the evidence in a 'Summary of findings\' table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome, and the rating of the overall certainty in effect estimates for each outcome. We used GRADEpro GDT to create the 'Summary of findings\' table ([@CD011526-bbs2-0027]).

### Measures of treatment effect {#CD011526-sec3-0010}

For continuous outcomes, we used mean differences (MD) as the measure of effect with 95% CIs. For outcomes with different measurements, for example stool output, which can be measured in grams or mL per kg, we used standardized mean differences (SMD). For dichotomous outcomes, we used risk ratios (RR) as the measure of effect with 95% CIs.

### Unit of analysis issues {#CD011526-sec3-0011}

Given the condition under study and the trial participants, we did not expect to find cluster randomized controlled trials or cross‐over trials. When we found trials with repeated measurements, we decided on a single time point (for example, diarrhoea resolution at day 3).

### Dealing with missing data {#CD011526-sec3-0012}

When there were no missing data, we carried out analyses according to the intention‐to‐treat principle, that is all children were analysed according to the group to which they were initially randomized. If there were missing data, we attempted to contact trial authors to request any missing data. If the trial authors did not respond within four to eight weeks, we conducted the analyses based on only the available information.

### Assessment of heterogeneity {#CD011526-sec3-0013}

We used forest plots to detect overlapping CIs, and applied the Chi^2^ test with a P value \< 0.10 to indicate statistical significance for heterogeneity. We investigated inconsistency with the I^2^ statistic, considering a value from 0% to 40% as not important.

### Assessment of reporting biases {#CD011526-sec3-0014}

We assessed reporting biases by examining asymmetry of funnel plots.

### Data synthesis {#CD011526-sec3-0015}

One review author (GP) analysed the data using Review Manager 5 ([@CD011526-bbs2-0038]). When appropriate, we combined data by meta‐analysis using a fixed‐effect model. When we found inconsistency (I^2^ statistic \> 40%) or heterogeneity (Chi^2^ test at a significant P value \< 0.10), we combined the results using the random‐effects model.

### Subgroup analysis and investigation of heterogeneity {#CD011526-sec3-0016}

We expected to perform subgroup analysis based on age groups, given that severity of disease might be different among infants, children, and adolescents. Since the higher burden and mortality of acute diarrhoea is in infants ([@CD011526-bbs2-0042]), we analysed subgroups under and over two years of age.

### Sensitivity analysis {#CD011526-sec3-0017}

We performed sensitivity analyses regarding risk of bias to investigate the robustness of the results, that is restricting the analysis by taking into account trials at low versus high or unclear risk of bias, as specified in the [Assessment of risk of bias in included studies](#CD011526-sec3-0009){ref-type="sec"} section. We explored if the following markers affected the direction of results: randomization, allocation concealment, blinding, follow‐up, and missing data. We also performed a sensitivity analysis excluding the trials that required estimations and figure extractions ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]).

Results {#CD011526-sec1-0005}
=======

Description of studies {#CD011526-sec2-0008}
----------------------

See: [Characteristics of included studies](#CD011526-sec2-0019){ref-type="sec"}; [Characteristics of excluded studies](#CD011526-sec2-0020){ref-type="sec"}; Characteristics of studies awaiting classification.

### Results of the search {#CD011526-sec3-0018}

Our search strategy identified 34 potentially relevant studies, of which 22 studies were screened in full text. Eighteen studies met the inclusion criteria, and four were excluded ([@CD011526-bbs2-0020]; [@CD011526-bbs2-0021]; [@CD011526-bbs2-0022]; [@CD011526-bbs2-0023]). The study flow diagram is shown in [Figure 1](#CD011526-fig-0001){ref-type="fig"}. One reference included two studies ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]). Another study is presented in the results as two separate studies because data were divided by age group ([@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]).Figure 1Study flow diagram.

### Included studies {#CD011526-sec3-0019}

#### Study location {#CD011526-sec4-0007}

Eleven studies were conducted in low‐ or middle‐income countries: Peru, Malaysia, Egypt, Thailand, India, Pakistan, Indonesia, and China ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0006]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0009]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0016]; [@CD011526-bbs2-0017]; [@CD011526-bbs2-0018]; [@CD011526-bbs2-0019]). Seven were conducted in high‐income countries: France, Italy, Lithuania, and Poland ([@CD011526-bbs2-0003]; [@CD011526-bbs2-0004]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0008]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]). Most trials were conducted in hospitals, with two studies conducted in both hospital and an ambulatory setting ([@CD011526-bbs2-0007]; [@CD011526-bbs2-0017]), three exclusively with outpatients ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0006]; [@CD011526-bbs2-0009]), and two that did not specify ([@CD011526-bbs2-0003]; [@CD011526-bbs2-0019]).

#### Participants {#CD011526-sec4-0008}

Most studies included infants aged one to 24 months. One study did not include infants ([@CD011526-bbs2-0009]), and one did not report age ([@CD011526-bbs2-0017]). Nine studies included children aged two to 12 years old. No trials included adolescents. Two trials included only males ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]). One report divided its results into two age groups: less than 12 months and 13 to 36 months ([@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]).

Two studies included exclusively breastfed infants ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]), and seven studies included children who were breastfed ([@CD011526-bbs2-0006]; [@CD011526-bbs2-0011]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0016]; [@CD011526-bbs2-0018]). One study excluded breastfed infants ([@CD011526-bbs2-0010]). Thirteen trials reported rotavirus as the most frequent gastroenteritis aetiology. No studies included dysentery or bloody diarrhoea or children with cholera. One study included children with moderate malnutrition ([@CD011526-bbs2-0018]), while the other studies excluded children with any degree of malnutrition.

Most trials defined diarrhoea as three or more loose stools, but the duration varied among studies: four defined it as less than two days ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0006]; [@CD011526-bbs2-0009]; [@CD011526-bbs2-0018]); six as less than three days ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0016]); one as less than four days ([@CD011526-bbs2-0005]); five as less than five days ([@CD011526-bbs2-0007]; [@CD011526-bbs2-0008]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0017]; [@CD011526-bbs2-0019]); one as less than seven days ([@CD011526-bbs2-0011]); and one referred to it as \"recent\" ([@CD011526-bbs2-0003]).

#### Interventions {#CD011526-sec4-0009}

Doses of smectite varied between 1 g and 6 g per dose, and frequency of administration varied from once daily to every six hours. Most trials used 1.5 g per dose in infants less one year and 3 g in older infants or children. Two trials administered 3 g twice a day for three days, and then once a day in infants less than one year, and double the dose in older children ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]). Five trials gave 1.5 g of smectite twice a day to infants less than one year, with double the dose for older children ([@CD011526-bbs2-0003]; [@CD011526-bbs2-0004]; [@CD011526-bbs2-0008]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]; [@CD011526-bbs2-0017]). Two studies gave a loading dose of 3 g ([@CD011526-bbs2-0006]; [@CD011526-bbs2-0010]). Two trials administered smectite every eight hours ([@CD011526-bbs2-0009]; [@CD011526-bbs2-0015]), and one study gave it every six hours ([@CD011526-bbs2-0007]). Two trials gave smectite every eight hours to children weighing less than 10 kg, and every six hours to children above 10 kg ([@CD011526-bbs2-0011]; [@CD011526-bbs2-0016]). Two studies gave *Lactobacillus rhamnosus* GG to both the intervention and the control group ([@CD011526-bbs2-0012]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]). Two studies did not report the dose ([@CD011526-bbs2-0018]; [@CD011526-bbs2-0019]).

The duration of treatment also differed among studies. Four studies gave smectite until recovery ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0012]); two administered the treatment for three days ([@CD011526-bbs2-0007]; [@CD011526-bbs2-0008]); five for five days ([@CD011526-bbs2-0009]; [@CD011526-bbs2-0011]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0016]; [@CD011526-bbs2-0018]); and one for six days ([@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]). The remaining studies did not specify the duration of treatment.

#### Outcomes {#CD011526-sec4-0010}

##### Primary outcomes {#CD011526-sec5-0001}

Fifteen studies reported the duration of diarrhoea ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0003]; [@CD011526-bbs2-0004]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0008]; [@CD011526-bbs2-0009]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0016]; [@CD011526-bbs2-0018]; [@CD011526-bbs2-0019]), but the outcome was defined differently. Six trials defined it as time to the last loose stool ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0016]; [@CD011526-bbs2-0018]); three as time to first formed stool ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0015]); one as time to first soft or formed stool ([@CD011526-bbs2-0002]); three as time to normalization of stools ([@CD011526-bbs2-0003]; [@CD011526-bbs2-0009]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]); and two did not provide a clear definition ([@CD011526-bbs2-0008]; [@CD011526-bbs2-0019]).

Five trials reported clinical resolution of diarrhoea at day 3 ([@CD011526-bbs2-0005]; [@CD011526-bbs2-0006]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0011]; [@CD011526-bbs2-0016]).

##### Secondary outcomes {#CD011526-sec5-0002}

Four studies reported stool frequency: three as number of depositions per day ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0011]), and one as the total number of stools during follow‐up ([@CD011526-bbs2-0008]). Three trials reported stool output as grams per kilogram of child\'s weight at 72 hours ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]), and one in grams per day ([@CD011526-bbs2-0011]). Two studies reported need for hospitalization ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0012]). One study reported need for intravenous access for rehydration ([@CD011526-bbs2-0012]). No studies reported deaths.

Risk of bias in included studies {#CD011526-sec2-0009}
--------------------------------

See: [Characteristics of included studies](#CD011526-sec2-0019){ref-type="sec"}; [Figure 2](#CD011526-fig-0002){ref-type="fig"}; [Figure 3](#CD011526-fig-0003){ref-type="fig"} for the risk of bias in included studies.Figure 2'Risk of bias\' graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.Figure 3'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD011526-sec3-0020}

Seven studies had an adequate description of randomization method ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0018]). In five trials the information about random allocation was unclear ([@CD011526-bbs2-0003]; [@CD011526-bbs2-0006]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]; [@CD011526-bbs2-0017]; [@CD011526-bbs2-0019]). Five studies were quasi‐randomized trials in which children were allocated alternately, by birthday or serial number ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0008]; [@CD011526-bbs2-0009]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0011]). We suspected selection bias in one study as groups differed in the aetiology of diarrhoea, and the method of randomization was not described ([@CD011526-bbs2-0016]).

Five studies adequately described allocation concealment ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0018]). We considered all quasi‐randomized trials as having high risk of bias regarding allocation concealment.

### Blinding {#CD011526-sec3-0021}

Eight trials were reported as double‐blind and used a placebo as control ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0003]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0012]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0018]). The remaining trials were not blinded ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0006]; [@CD011526-bbs2-0008]; [@CD011526-bbs2-0009]; [@CD011526-bbs2-0010]; [@CD011526-bbs2-0011]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]; [@CD011526-bbs2-0016]; [@CD011526-bbs2-0017]; [@CD011526-bbs2-0019]).

### Incomplete outcome data {#CD011526-sec3-0022}

Fourteen trials had appropriate follow‐up and analysis of more than 90% of participants. Two included less than 90% in the analysis ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0011]). In one trial information was insufficient to permit judgement ([@CD011526-bbs2-0004]).

### Selective reporting {#CD011526-sec3-0023}

Two trials had a registered protocol ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]).

Effects of interventions {#CD011526-sec2-0010}
------------------------

See: [Table 1](#CD011526-tbl-0001){ref-type="table"}

### Primary outcomes {#CD011526-sec3-0024}

#### 1.1 Duration of diarrhoea {#CD011526-sec4-0011}

Overall, duration of diarrhoea was reduced by approximately 24 hours (mean difference (MD) ‐24.38, 95% confidence interval (CI) ‐30.91 to ‐17.85; 14 trials; 2209 children, [Analysis 1.1](#CD011526-fig-00101){ref-type="fig"}; low‐certainty evidence). There was significant heterogeneity (I^2^ = 96%). This high inconsistency was due to differences in effect size of the benefit, not because of opposing directions of effects ([Figure 4](#CD011526-fig-0004){ref-type="fig"}).Figure 4Forest plot of comparison: 1 Diarrhoea primary outcomes, outcome: 1.1 Mean duration of diarrhoea (hours).

A sensitivity analysis exploring the effect of randomization, allocation concealment, blinding, and follow‐up did not change the result of the meta‐analysis significantly. Sensitivity analysis excluding the trials that required estimations and figure extractions did not significantly change the result of the meta‐analysis (MD ‐22.07, 95% CI ‐30.38 to ‐13.76) ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]).

On visual inspection, the funnel plot was roughly symmetric, with most studies centred together at the top, probably reflecting spuriously small standard deviations of the continuous outcome that is skewed ([Figure 5](#CD011526-fig-0005){ref-type="fig"}).Figure 5Funnel plot of comparison: 1 Diarrhoea primary outcomes, outcome: 1.1 Mean duration of diarrhoea (hours).

#### 1.2 Duration of diarrhoea, infants less than two years {#CD011526-sec4-0012}

Five studies included only infants younger than two years ([@CD011526-bbs2-0003]; [@CD011526-bbs2-0005]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0015]; [@CD011526-bbs2-0016]). One study reported results for infants less than 12 months ([@CD011526-bbs2-0013]). Smectite reduced the duration of diarrhoea by 24 hours (MD ‐24.11, 95% CI ‐31.35 to ‐16.87; 441 infants; [Analysis 1.2](#CD011526-fig-00102){ref-type="fig"}). Other studies included both infants and children, but they did not provide enough information to be able to perform a subgroup analysis according to age ([Figure 6](#CD011526-fig-0006){ref-type="fig"}).Figure 6Forest plot of comparison: 1 Diarrhoea primary outcomes, outcome: 1.2 Mean duration of diarrhoea, studies including only infants \< 2 years.

#### 1.3 Clinical resolution at day 3 after starting treatment {#CD011526-sec4-0013}

Smectite increased the rate of clinical resolution at day 3 (risk ratio (RR) 2.10, 95% CI 1.30 to 3.39; 5 trials; 312 children; [Analysis 1.3](#CD011526-fig-00103){ref-type="fig"}; low‐certainty evidence) ([Figure 7](#CD011526-fig-0007){ref-type="fig"}). After performing a sensitivity analysis excluding trials with high risk of bias ([@CD011526-bbs2-0011]; [@CD011526-bbs2-0016]), the pooled effect was not significant (RR 1.90, 95% CI 0.96 to 3.77; 3 trials; 190 children).Figure 7Forest plot of comparison: 1 Diarrhoea primary outcomes, outcome: 1.3 Clinical resolution at day 3 after starting treatment.

### Secondary outcomes {#CD011526-sec3-0025}

#### 2.1 Stool frequency {#CD011526-sec4-0014}

Three studies measured stool frequency as number of depositions per day, all of them reporting data on day 3 ([@CD011526-bbs2-0004]; [@CD011526-bbs2-0007]; [@CD011526-bbs2-0011]). Smectite reduced stool frequency by one (MD ‐1.33, 95% CI ‐2.28 to ‐0.38; 3 trials; 954 children; [Analysis 2.1](#CD011526-fig-00201){ref-type="fig"}; very low‐certainty evidence) ([Figure 8](#CD011526-fig-0008){ref-type="fig"}). One study measured stool frequency as total number of depositions during follow‐up; the mean number of depositions was 10 in both groups ([@CD011526-bbs2-0008]).Figure 8Forest plot of comparison: 2 Diarrhoea secondary outcomes, outcome: 2.1 Stool frequency, measured as number of depositions per day, on day 3 after starting treatment.

#### 2.2 Stool output {#CD011526-sec4-0015}

Four studies evaluated stool output. Three studies reported cumulative stool output at 72 hours ([@CD011526-bbs2-0001]; [@CD011526-bbs2-0002]; [@CD011526-bbs2-0007]). Smectite reduced stool output by 11 g/kg (MD ‐11.37, 95% CI ‐21.94 to ‐0.79; 3 trials; 634 children; [Analysis 2.2](#CD011526-fig-00202){ref-type="fig"}; low‐certainty evidence) ([Figure 9](#CD011526-fig-0009){ref-type="fig"}). Another study was not pooled because the authors reported stool output as stool weight in total grams per day with an effect estimate favouring smectite (mean of 255.67 g in the smectite group versus 741.33 g in the control group) at day 3 of treatment ([@CD011526-bbs2-0011]).Figure 9Forest plot of comparison: 2 Diarrhoea secondary outcomes, outcome: 2.2 Stool output, measured in g/kg at 72 hours.

#### 2.3 Need for hospitalization {#CD011526-sec4-0016}

Two studies reported data on need for hospitalization. There was no evidence of benefit using smectite (RR 0.93, 95% CI 0.75 to 1.15; 2 trials; 885 children; [Analysis 2.3](#CD011526-fig-00203){ref-type="fig"}; low‐certainty evidence) ([Figure 10](#CD011526-fig-0010){ref-type="fig"}).Figure 10Forest plot of comparison: 2 Diarrhoea secondary outcomes, outcome: 2.3 Need for hospitalization.

#### 2.4 Need for intravenous access for rehydration {#CD011526-sec4-0017}

There was no evidence of an effect on need for intravenous rehydration (RR 0.77, 95% CI 0.54 to 1.11; 1 trial; 81 children; [Analysis 2.4](#CD011526-fig-00204){ref-type="fig"}; moderate‐certainty evidence).

#### 2.5 Death (from any cause or diarrhoea‐related) {#CD011526-sec4-0018}

No deaths were reported in any of the included trials.

#### 2.6 Serious adverse events (life‐threatening events) {#CD011526-sec4-0019}

There were no reports of serious adverse events.

#### 2.7 Other adverse events (constipation, vomiting) {#CD011526-sec4-0020}

The most commonly reported adverse effect was constipation. However, the risk of constipation using smectite was very uncertain due to imprecision, with very few events and wide confidence intervals (RR 4.71, 95% CI 0.56 to 39.19; 2 trials; 128 children; [Analysis 2.5](#CD011526-fig-00205){ref-type="fig"}; low‐certainty evidence) ([Figure 11](#CD011526-fig-0011){ref-type="fig"}). There were also no differences between groups regarding vomiting or fever. Another minor adverse event mentioned in trials was bad taste, but there were no specific numbers for the intervention and control groups.Figure 11Forest plot of comparison: 2 Diarrhoea secondary outcomes, outcome: 2.5 Constipation.

Discussion {#CD011526-sec1-0006}
==========

Summary of main results {#CD011526-sec2-0011}
-----------------------

We identified 18 studies that compared smectite to a control group. Overall, smectite reduced the duration of diarrhoea by approximately a day, increased clinical resolution by day 3, and had a modest benefit on stool frequency and output. This evidence of benefit persisted after a sensitivity analysis accounting for randomization method, even though five trials were quasi‐randomized. Eight trials reported the inclusion of breastfed infants.

There was no evidence of an effect on the need for hospitalization or intravenous rehydration, deaths, or serious side effects.

Overall completeness and applicability of evidence {#CD011526-sec2-0012}
--------------------------------------------------

Studies were conducted in diverse settings in both high‐income and low‐ or middle‐income countries, and including both ambulatory and hospital patients. Aetiology also varied, with most trials including a large proportion of children with rotavirus. Most studies excluded children with malnutrition. Most of the studies were funded by the industry. Although external funding and commercial interests are well recognized as a potential source of bias in clinical trials, most investigators provided reasonable information that shows that the manufacturers had no, or a very limited, active role in the design and conduct of the studies.

Quality of the evidence {#CD011526-sec2-0013}
-----------------------

We assessed the certainty of the evidence using the GRADE system, which is displayed in 'Summary of findings\' table 1 ([Table 1](#CD011526-tbl-0001){ref-type="table"}). Overall, the certainty of the body of evidence ranged from very low to moderate. For our primary outcomes, the certainty of evidence was low mainly due to concerns of risk of bias and inconsistency of the results. Regarding risk of bias, we included four quasi‐randomized trials, and another four trials did not clearly describe the randomization process. Also, seven trials were not blinded.

The high heterogeneity observed may be due to differences in the definition of the condition, the age of participants, and the different aetiologies. In one study, [@CD011526-bbs2-0012], another explanation for heterogeneity could be that both the intervention and the control group received a probiotic, but the other study that added a probiotic as a co‐intervention did not contribute to such inconsistency ([@CD011526-bbs2-0013]; [@CD011526-bbs2-0014]). The high inconsistency observed was mainly due to differences in effect size of the benefit and not because of opposing directions of effects.

Potential biases in the review process {#CD011526-sec2-0014}
--------------------------------------

We made every attempt to limit biases during the review process by ensuring a comprehensive search for potentially eligible studies. We believe that the authors' independent assessments of eligibility of studies for inclusion and data extraction have minimized the potential for additional bias beyond that detailed in the 'Risk of bias\' tables in the [Characteristics of included studies](#CD011526-sec2-0019){ref-type="sec"} and in the funnel plot.

Agreements and disagreements with other studies or reviews {#CD011526-sec2-0015}
----------------------------------------------------------

Our findings agree with those of previous systematic reviews ([@CD011526-bbs2-0025]; [@CD011526-bbs2-0040]). Due to the differences in time of publication, our review includes more trials than the review by [@CD011526-bbs2-0040], and assesses the certainty of the evidence based on the GRADE approach. The review by [@CD011526-bbs2-0025] included 13 out of the 18 studies that were included in this review. [@CD011526-bbs2-0040] reported a reduction of 22.7 hours in the duration of diarrhoea, while [@CD011526-bbs2-0025] reported 22.39 hours. [@CD011526-bbs2-0040] and [@CD011526-bbs2-0025] also report significant results for cure rate at day 3. While [@CD011526-bbs2-0025] reported clinical resolution at day 5 and 7, we considered day 3 to be more clinically relevant.

Authors\' conclusions {#CD011526-sec1-0007}
=====================

Smectite reduces the duration of symptoms of infectious diarrhoea by a day, and at least 17 hours, and increases clinical resolution at day 3. The effect on stool frequency and output is modest. Although smectite did not have an effect on other relevant outcomes such as the need for intravenous therapy or hospitalization, fewer hours of diarrhoea may be considered clinically significant in different settings and contexts, taking into account that most cases of infectious diarrhoea are self limited and resolve within three to five days with adequate hydration and medical care.Further research with a focus on adequate randomization and blinding is needed. Future studies may explore the causes of heterogeneity in the effect of smectite, its possible benefit in vulnerable populations such as children under two years of age or with malnutrition, and its effect on certain specific aetiologies such as rotavirus or dysentery producing bacteria. Economic analyses will also provide information to guide practice in different countries or settings.

The editorial base for the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of low‐ and middle‐income countries (Grant: 5242).

**Search setCIDG SR^a^CENTRALMEDLINE^b^Embase^b^LILACS^b^**1smectiteSmectite \[Supplementary concept\]Smectite \[Supplementary concept\]Smectite ti, absmectite2diosmectitesmectite\* ti, absmectite\* ti, abDiosmectite ti, abdiosmectite31 or 2Diosmectite ti, abDiosmectite ti, ab1 or 21 or 24--\"smecta\"\[Supplementary Concept\]\"smecta\"\[Supplementary Concept\]Limit 3 to human‐5‐1 or 2 or 3 or 41 or 2 or 3 or 4‐‐6‐Limit 5 to humansLimit 5 to humans‐‐^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([@CD011526-bbs2-0035]); upper case: MeSH or EMTREE heading; lower case: free text term.

Comparison 1Diarrhoea primary outcomesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mean duration of diarrhoea](#CD011526-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Diarrhoea primary outcomes, Outcome 1 Mean duration of diarrhoea.152209Mean Difference (IV, Random, 95% CI)‐24.38 \[‐30.91, ‐17.85\][2 Mean duration of diarrhoea, studies including only infants \< 2 years](#CD011526-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Diarrhoea primary outcomes, Outcome 2 Mean duration of diarrhoea, studies including only infants \< 2 years.6441Mean Difference (IV, Random, 95% CI)‐24.11 \[‐31.35, ‐16.87\][3 Clinical resolution at day 3 after starting treatment](#CD011526-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Diarrhoea primary outcomes, Outcome 3 Clinical resolution at day 3 after starting treatment.5312Risk Ratio (M‐H, Random, 95% CI)2.10 \[1.30, 3.39\]

Comparison 2Diarrhoea secondary outcomesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Stool frequency, measured as number of depositions per day, on day 3 after starting treatment](#CD011526-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Diarrhoea secondary outcomes, Outcome 1 Stool frequency, measured as number of depositions per day, on day 3 after starting treatment.3954Mean Difference (IV, Random, 95% CI)‐1.33 \[‐2.28, ‐0.38\][2 Stool output, measured in g or mL/kg per day](#CD011526-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Diarrhoea secondary outcomes, Outcome 2 Stool output, measured in g or mL/kg per day.3634Mean Difference (IV, Random, 95% CI)‐11.37 \[‐21.94, ‐0.79\][3 Need for hospitalization](#CD011526-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Diarrhoea secondary outcomes, Outcome 3 Need for hospitalization.2885Risk Ratio (M‐H, Random, 95% CI)0.93 \[0.75, 1.15\][4 Need for intravenous access for rehydration](#CD011526-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Diarrhoea secondary outcomes, Outcome 4 Need for intravenous access for rehydration.181Risk Ratio (M‐H, Random, 95% CI)0.77 \[0.54, 1.11\][5 Constipation](#CD011526-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Diarrhoea secondary outcomes, Outcome 5 Constipation.2128Risk Ratio (M‐H, Random, 95% CI)4.71 \[0.56, 39.19\]

We added Ivan D Florez as an author.

Characteristics of included studies \[ordered by study ID\] {#CD011526-sec2-0019}
===========================================================

[@CD011526-bbs2-0001]MethodsRandomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 300 enrolled children\
Inclusion criteria: inpatients; well‐nourished male infants and children aged 1 to 36 months with watery diarrhoea \< 3 days duration, with 3 watery stools per day and at least 1 watery stool in the past 24 hours; mild‐to‐moderate dehydration\
Exclusion criteria: severe dehydration or malnutrition, bloody diarrhoea, fever 39 ºC or higher, previous medications\
Breastfeeding: exclusively breastfed infants were excludedInterventionsIntervention group: diosmectite. Dosage 3 g twice a day for 3 days, then 3 g daily for infants younger than 12 months. Double the dose for older children\
Control: placeboOutcomesDuration of diarrhoea (until first formed stool)\
Stool output in g/kg in the first 72 hrsNotesLocation: Peru\
Setting: urban\
Cause of diarrhoea: rotavirus 22%. Other aetiologies not specified.\
Source of funding: industry\
Registration number: NCT00352716***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskDescribed as randomized in sequential ascending order by a statisticianAllocation concealment (selection bias)Low riskSponsor‐assigned biostatistician prepared a list of treatment allocation codes.Blinding of participants and personnel (performance bias) All outcomesLow riskPlacebo was identical to diosmectite in size, weight, colour, smell, taste, and appearance, and was inert. Blinding seems appropriate.Blinding of outcome assessment (detection bias) All outcomesLow riskBlind review of data by outcome assessorsIncomplete outcome data (attrition bias) All outcomesHigh risk40 children (13%) were non‐adherent, and the rest analysed as per protocol.Selective reporting (reporting bias)Low riskNone detected. Registered trialOther biasLow riskNo other biases detected.[@CD011526-bbs2-0002]MethodsRandomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 302 enrolled children\
Inclusion criteria: inpatients; well‐nourished male infants and children aged 1 to 36 months with watery diarrhoea \< 3 days duration, with 3 watery stools per day and at least 1 watery stool in the past 24 hours; mild‐to‐moderate dehydration\
Exclusion criteria: severe dehydration or malnutrition, bloody diarrhoea, fever 39 ºC or higher, previous medications\
Breastfeeding: exclusively breastfed infants were excludedInterventionsIntervention group: diosmectite. Dosage 3 g twice a day for 3 days, then 3 g daily for infants younger than 12 months. Double the dose for older children\
Control: placeboOutcomesDuration of diarrhoea (until first soft or formed stool)\
Stool output in g/kg in the first 72 hrsNotesLocation: Malaysia\
Setting: urban\
Cause of diarrhoea: rotavirus 12%. Other aetiologies not specified.\
Source of funding: industry\
Registration number: NCT00352989***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskDescribed as randomized in sequential ascending order by a statisticianAllocation concealment (selection bias)Low riskSponsor‐assigned biostatistician prepared a list of treatment allocation codes.Blinding of participants and personnel (performance bias) All outcomesLow riskPlacebo was identical to diosmectite in size, weight, colour, smell, taste, and appearance, and was inert. Blinding seems appropriate.Blinding of outcome assessment (detection bias) All outcomesLow riskBlind review of data by outcome assessorsIncomplete outcome data (attrition bias) All outcomesLow risk16 children (5%) were non‐adherent, and the rest analysed as per protocol.Selective reporting (reporting bias)Low riskNone detected. Registered trialOther biasLow riskNo other biases detected.[@CD011526-bbs2-0003]MethodsRandomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 56 enrolled children\
Inclusion criteria: inpatients; children aged 2 to 24 months with moderate‐to‐severe acute diarrhoea\
Exclusion criteria: malnutrition\
Breastfeeding: not specifiedInterventionsIntervention group: diosmectite. Dosage 1.5 g twice a day for infants younger than 12 months. Double the dose for older children\
Control: placebo\
Another control group received loperamide 0.11 mg/kg every 8 hours.OutcomesDuration of diarrhoea (time to normalization of stools)\
Stool frequency on day 5NotesLocation: France\
Setting: urban\
Cause of diarrhoea: rotavirus 18%, *Staphylococcus aureus* 3%, *Escherichia coli* 3%, *Campylobacter* spp. 3%, *Candida* spp. 1%\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskStated as randomized but no method described.Allocation concealment (selection bias)Unclear riskNo method described.Blinding of participants and personnel (performance bias) All outcomesLow riskUse of placebo; probably adequate blindingBlinding of outcome assessment (detection bias) All outcomesUnclear riskInsufficient information to permit judgementIncomplete outcome data (attrition bias) All outcomesLow riskPer‐protocol analysis. 4 children (7%) excluded and not analysed.Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0004]MethodsQuasi‐randomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 804 enrolled children\
Inclusion criteria: outpatients; well‐nourished children aged 3 to 60 months with acute diarrhoea of mild‐to‐moderate severity \< 2 days duration, with 3 watery stools per day\
Exclusion criteria: malnutrition, chronic diseases, previous medications\
Breastfeeding: not specifiedInterventionsIntervention group: diosmectite. Dosage 1.5 g twice a day for infants younger than 12 months. Double the dose for older children\
Control: no medicationOutcomesDuration of diarrhoea (from first to the last liquid--loose stool output preceding the return of normal stools)\
Diarrhoea at day 7\
Vomiting\
Fever\
Hospitalization rateNotesLocation: Italy\
Setting: urban\
Cause of diarrhoea: rotavirus 4%, not specified bacterial aetiology 1%\
Source of funding: industry***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNot randomized. Participants selected in sequential one‐to‐one basis.Allocation concealment (selection bias)High riskNot concealedBlinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesUnclear riskInsufficient information to permit judgementSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0005]MethodsRandomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 36 enrolled infants\
Inclusion criteria: inpatients; infants aged 2 to 24 months with acute watery diarrhoea \< 4 days duration, with mild‐to‐moderate dehydration\
Exclusion criteria: previous medications, concomitant illness\
Breastfeeding: not statedInterventionsIntervention group: diosmectite. Dosage 3 g per day to infants \< 1 year, 6 g per day to infants \> 1 year. Duration not stated.\
Control: placeboOutcomesDuration of diarrhoea (from first drug administration to last liquid stool before a formed one)\
Clinical resolution at day 3 and 5\
Adverse eventsNotesLocation: France\
Setting: urban\
Cause of diarrhoea: rotavirus 77%\
Source of funding: not specified***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStated as \"drawing lots\"Allocation concealment (selection bias)Unclear riskInsufficient information to permit judgementBlinding of participants and personnel (performance bias) All outcomesLow riskUse of placebo; probably adequate blindingBlinding of outcome assessment (detection bias) All outcomesUnclear riskUse of placebo; probably adequate blindingIncomplete outcome data (attrition bias) All outcomesLow riskOnly 1 loss per groupSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0006]MethodsRandomized controlled trial\
Length of follow‐up: 5 daysParticipantsNumber: 66 enrolled children\
Inclusion criteria: outpatients; well‐nourished children aged 1 to 24 months with acute diarrhoea \< 2 days duration, with 3 watery stools within 24 hours\
Exclusion criteria: severe dehydration, dysentery, fever higher than 38.5 ºC, previous medications\
Breastfeeding: includedInterventionsIntervention group: diosmectite. Dosage: loading dose of 3 g, then 1.5 g twice a day\
Control: no medicationOutcomesDiarrhoea at day 3 and 5\
TolerabilityNotesLocation: Thailand\
Setting: urban\
Cause of diarrhoea: rotavirus 27%, *Campylobacter jejuni* 8%, enteropathogenic *Escherichia coli* 5%, *Salmonella* spp. 6%, *Shigella* spp. 3%, *Plesiomonas shigelloides* 2%\
Source of funding: industry***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskStated as randomized. No method described.Allocation concealment (selection bias)Unclear riskNo method described.Blinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0007]MethodsRandomized controlled trial\
Length of follow‐up: until recovery from diarrhoeaParticipantsNumber: 90 enrolled children\
Inclusion criteria: inpatients; well‐nourished male children aged 3 to 24 months with watery diarrhoea \< 5 days duration, with dehydration of any severity\
Exclusion criteria: prolonged diarrhoea, malnutrition, major illnesses\
Breastfeeding: not specifiedInterventionsIntervention group: diosmectite. Dosage 1.5 g, 4 times daily for 3 days\
Control group: placeboOutcomesDuration of diarrhoea (from enrolment to last liquid stool)\
Frequency of diarrhoea\
Duration of vomiting\
Feeding patternNotesLocation: Egypt\
Setting: urban\
Cause of diarrhoea: rotavirus 16%. Other aetiologies not specified.\
Source of funding: WHO and industry***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomization by Diarrheal Disease Control Programme of the WHOAllocation concealment (selection bias)Low riskNumerically coded envelopesBlinding of participants and personnel (performance bias) All outcomesLow riskUse of placeboBlinding of outcome assessment (detection bias) All outcomesLow riskUse of placeboIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0008]MethodsQuasi‐randomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 35 enrolled children\
Inclusion criteria: inpatients; children aged 0 to 60 months with watery diarrhoea \< 5 days duration\
Exclusion criteria: not stated\
Breastfeeding: not specifiedInterventionsIntervention group: diosmectite. Dosage 1.5 g twice a day for infants younger than 12 months. Double the dose for older children\
Control: no medicationOutcomesNumber of stools at 48 hrs\
Duration of diarrhoea (not clearly defined)\
Fever, vomiting, weight lossNotesLocation: Italy\
Setting: urban\
Cause of diarrhoea: rotavirus 23%, *Salmonella* spp. 11%, *Cryptosporidium* 6%\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskParticipants selected \"alternatively\"; not truly random.Allocation concealment (selection bias)High riskNot concealedBlinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow risk2 losses to follow‐up in intervention groupSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0009]MethodsQuasi‐randomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 117 enrolled children\
Inclusion criteria: outpatients; well‐nourished children aged 24 to 60 months with watery diarrhoea \< 2 days duration; mild‐to‐moderate dehydration\
Exclusion criteria: bloody diarrhoea, chronic illness, previous medications\
Breastfeeding: not specifiedInterventionsIntervention group: diosmectite. Dosage 1.5 g thrice a day for 5 days\
Control group: no medicationOutcomesDuration of diarrhoea (until normal stool consistency)\
Complications: severe dehydration, severe dysentery, respiratory infection, and anaemiaNotesLocation: India\
Setting: urban\
Cause of diarrhoea: not specified\
Source of funding: not specified***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNot truly random; participants selected by serial number.Allocation concealment (selection bias)High riskNot concealedBlinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskIntention‐to‐treat analysis. 8 children (7%) were lost to follow‐up and were included in the analysis.Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0010]MethodsQuasi‐randomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 54 enrolled children\
Inclusion criteria: inpatients; well‐nourished infants and children aged 6 to 48 months with watery diarrhoea \< 3 days duration, with 3 watery stools per day; mild‐to‐moderate dehydration\
Exclusion criteria: severe dehydration, malnutrition, chronic or concomitant illness\
Breastfeeding: excludedInterventionsIntervention group: diosmectite. Dosage: loading dose of 3 g; 1.5 g, 3 times a day for children \< 10 kg, 4 times a day for \> 10 kg\
Control: no medicationOutcomesDuration of diarrhoea (time to last watery/semiliquid stool)\
Length of stayNotesLocation: Lithuania\
Setting: urban\
Cause of diarrhoea: rotavirus 70%, enteropathogenic *Escherichia coli* 4%, *Campylobacter* spp. 8%\
Source of funding: industry***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNot truly random; participants selected by birthday.Allocation concealment (selection bias)High riskNot concealedBlinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0011]MethodsQuasi‐randomized controlled trial\
Length of follow‐up: 5 daysParticipantsNumber: 71 infants and children\
Inclusion criteria: inpatients; infants and children (no age limit specified, mean age of 13 months) with acute watery diarrhoea \< 7 days duration, with mild‐to‐moderate dehydration\
Exclusion criteria: systemic illness; previous use of antibiotics or antidiarrhoeal agents; malnutrition\
Breastfeeding: includedInterventionsIntervention group: diosmectite. Dosage 1.5 g every 8 hours to infants \< 10 kg, 1.6 g every 6 hours to infants \> 10 kg for a maximum of 5 days\
Control: no medicationOutcomesClinical resolution (return of stools to previous formed consistency and average number of frequency)\
Stool output (g/kg)\
Stool frequencyNotesLocation: Egypt\
Setting: urban\
Cause of diarrhoea: rotavirus 43%, bacterial (not specified) 23%\
Source of funding: not specified***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNot truly random; participants selected alternately.Allocation concealment (selection bias)High riskNot concealedBlinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesHigh riskPer‐protocol analysis with 4 exlusions in intervention group (12%) and 7 losses in control group (19%)Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasUnclear riskNo other biases detected.[@CD011526-bbs2-0012]MethodsRandomized controlled trial\
Length of follow‐up: 7 daysParticipantsNumber: 88 enrolled children\
Inclusion criteria: inpatients/outpatients; well‐nourished infants and children aged 4 to 60 months with watery diarrhoea \< 5 days duration, with 3 watery stools per day\
Exclusion criteria: recent history of diarrhoea, chronic diseases\
Breastfeeding: includedInterventionsIntervention group: diosmectite, dose 3 g once daily until diarrhoea stopped, plus *Lactobacillus* GG, dose of 6 x 10^9^ colony forming units, once daily for 7 days\
Control group: placebo plus *Lactobacillus* GGOutcomesDuration of diarrhoea (time from randomization until the last watery stool, or at least 12 h with no stool)\
Stool frequency\
Consistency of stools\
Need for antibiotic therapy\
Diarrhoea recurrence\
Need for hospitalization\
Need for intravenous rehydration therapyNotesLocation: Poland\
Setting: urban\
Cause of diarrhoea: rotavirus 60%, adenovirus 5%, *Salmonella* spp. 5%, *Staphylococcus aureus* 3%, enteropathogenic *Escherichia coli* 1%\
Source of funding: Medical University of Warsaw***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated block randomizationAllocation concealment (selection bias)Low riskRandomization prepared by independent investigator.Blinding of participants and personnel (performance bias) All outcomesLow riskUse of placeboBlinding of outcome assessment (detection bias) All outcomesLow riskUse of placeboIncomplete outcome data (attrition bias) All outcomesLow riskPer‐protocol analysis with 7 losses in control group (8%)Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0013]MethodsRandomized controlled trial\
Length of follow‐up: 28 daysParticipantsNumber: 56 enrolled infants\
Inclusion criteria: inpatients; well‐nourished infants ≤ 12 months with watery diarrhoea of rotaviral aetiology \< 3 days duration, with moderate dehydration\
Exclusion criteria: chronic diseases, aetiologies other than rotavirus\
Breastfeeding: includedInterventionsIntervention group: diosmectite, dose 1.5 g twice daily for 6 days, plus *Lactobacillus* GG in \"age dependent dose\"\
Control group: *Lactobacillus* GG\
A third group received polyvinylpolypyrrolidone plus *Lactobacillus* GG.OutcomesDuration of intravenous rehydration\
Duration of fever and vomiting\
Duration of diarrhoea (time to normalization of consistency of the stool or a day without stool)\
Need of hospitalization after dischargeNotesLocation: Poland\
Setting: urban\
Cause of diarrhoea: rotavirus 100%\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskStated as randomized. No method described.Allocation concealment (selection bias)Unclear riskNo method described.Blinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasUnclear riskNo other biases detected.[@CD011526-bbs2-0014]MethodsRandomized controlled trial\
Length of follow‐up: 28 daysParticipantsNumber: 105 enrolled infants\
Inclusion criteria: inpatients; well‐nourished infants \> 12 months with watery diarrhoea of rotaviral aetiology \< 3 days duration, with moderate dehydration\
Exclusion criteria: chronic diseases, aetiologies other than rotavirus\
Breastfeeding: includedInterventionsIntervention group: diosmectite, dose 3 g twice daily for 6 days, plus *Lactobacillus* GG in \"age dependent dose\"\
Control group: *Lactobacillus* GG\
A third group received polyvinylpolypyrrolidone plus *Lactobacillus* GG.OutcomesDuration of intravenous rehydration\
Duration of fever and vomiting\
Duration of diarrhoea (time to normalization of consistency of the stool or a day without stool)\
Need of hospitalization after dischargeNotesLocation: Poland\
Setting: urban\
Cause of diarrhoea: rotavirus 100%\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskStated as randomized. No method described.Allocation concealment (selection bias)Unclear riskNo method described.Blinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasUnclear riskNo other biases detected.[@CD011526-bbs2-0015]MethodsRandomized controlled trial\
Length of follow‐up: 6 daysParticipantsNumber: 206 enrolled children\
Inclusion criteria: inpatients; well‐nourished infants and children aged 6 to 24 months with watery diarrhoea \< 3 days duration, with 3 watery stools per day and at least 1 in the past 24 hours; mild‐to‐severe dehydration\
Exclusion criteria: bloody diarrhoea, medications, malnutrition, systemic infection\
Breastfeeding: includedInterventionsIntervention group: diosmectite, dose 1 g in infants \< 12 months and 1.5 g in older children, every 8 hours, plus zinc (dose not specified) for 5 days\
Control group: placebo plus zincOutcomesDuration of diarrhoea (until first stool of pre‐diarrhoeal consistency)NotesLocation: Pakistan\
Setting: urban\
Cause of diarrhoea: not specified\
Source of funding: not specified***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomized by lotteryAllocation concealment (selection bias)Unclear riskInsufficient information to permit judgement. Mentions only \"lottery method\".Blinding of participants and personnel (performance bias) All outcomesLow riskUse of placeboBlinding of outcome assessment (detection bias) All outcomesLow riskUse of placeboIncomplete outcome data (attrition bias) All outcomesLow riskPer‐protocol analysis. 10 losses to follow‐up (5%), 4 in intervention group, 6 in control groupSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0016]MethodsRandomized controlled trial\
Length of follow‐up: 5 daysParticipantsNumber: 62 enrolled children\
Inclusion criteria: inpatients; infants/children aged 1 to 24 months with acute secretory diarrhoea \< 3 days duration, with 3 watery stools per day\
Exclusion criteria: severe dehydration, third‐degree malnutrition, other medications, chronic illnesses\
Breastfeeding: includedInterventionsIntervention group: diosmectite. Dosage 1.5 g, every 12 hrs for infants \< 3 kg; every 8 hrs for infants 4 to 10 kg; every 6 hrs for children 11 to 15 kg, for a maximum of 5 days\
Control: no medicationOutcomesDuration of diarrhoea (from first intervention dose until last liquid stool)\
Number of stools\
Change in weight\
Oral liquid intakeNotesLocation: Thailand\
Setting: urban\
Cause of diarrhoea: rotavirus in 3% of children in intervention group, 19% in control group. Stool cultures were reported positive for *Salmonella* and *Aeromonas* spp. in 7% and 9% of children in the control and study group, respectively, but numbers of each bacterial aetiology per group were not stated.\
Source of funding: industry***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskStated as randomized, but no method of randomization described. Selection bias is suspected as groups were different in the aetiology of diarrhoea.Allocation concealment (selection bias)Unclear riskInsufficient information to permit judgementBlinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo children were lost to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases were detected.[@CD011526-bbs2-0017]MethodsRandomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 55 enrolled children\
Inclusion criteria: acute diarrhoea \< 5 days duration. No age limit or other inclusion criteria stated.\
Exclusion criteria: not stated\
Breastfeeding: not statedInterventionsIntervention group: diosmectite. Dosage 3 g per day in infants \< 1 year old, 6 g per day in \> 1 year\
Control: Bismuth complex. Dosage 5 mL, 3 times per dayOutcomesClinical resolution at day 5NotesLocation: China\
Setting: not clear\
Cause of diarrhoea: not reported\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo method of randomization described.Allocation concealment (selection bias)Unclear riskNo method described.Blinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0018]MethodsRandomized controlled trial\
Length of follow‐up: until recoveryParticipantsNumber: 68 enrolled infants\
Inclusion criteria: inpatients; infants aged 6 to 12 months with watery diarrhoea \< 2 days duration, with 3 watery stools per day and mild‐to‐moderate dehydration\
Exclusion criteria: severe malnutrition, bloody diarrhoea, severe disease\
Breastfeeding: includedInterventionsIntervention group: diosmectite. Dose not specified.\
Control group: placeboOutcomesDuration of diarrhoea (time until normal consistency and frequency)NotesLocation: Indonesia\
Setting: urban\
Cause of diarrhoea: not specified\
Source of funding: industry***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomizationAllocation concealment (selection bias)Low riskCoded, sealed envelopesBlinding of participants and personnel (performance bias) All outcomesLow riskUse of placeboBlinding of outcome assessment (detection bias) All outcomesLow riskUse of placeboIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[@CD011526-bbs2-0019]MethodsRandomized controlled trial\
Length of follow‐up: not statedParticipantsNumber: 45 enrolled children\
Inclusion criteria: infants and children aged 2 to 30 months with watery diarrhoea of \< 5 days duration\
Exclusion criteria: not specified\
Breastfeeding: not reportedInterventionsIntervention group: diosmectite. Dose not specified.\
Control: lactein tablet. Dose not specified.\
A third group received diosmectite and antibiotics.OutcomesDuration of diarrhoea (not clearly defined)NotesLocation: China\
Setting: unclear\
Cause of diarrhoea: rotavirus 100%\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo method of randomization described.Allocation concealment (selection bias)Unclear riskNo method described.Blinding of participants and personnel (performance bias) All outcomesHigh riskNot blindedBlinding of outcome assessment (detection bias) All outcomesHigh riskNot blindedIncomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐upSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement. No protocol registered.Other biasLow riskNo other biases detected.[^3]

Characteristics of excluded studies \[ordered by study ID\] {#CD011526-sec2-0020}
===========================================================

StudyReason for exclusion[@CD011526-bbs2-0020]Wrong outcome: permeability to mannitol and lactulose[@CD011526-bbs2-0021]Wrong outcome: permeability to mannitol and lactulose[@CD011526-bbs2-0022]Wrong population: neonates[@CD011526-bbs2-0023]Duplicate
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^Four trials are quasi‐randomized and without adequate blinding of participants. ^2^High heterogeneity (I^2^ = 96%) among studies that may be explained by differences in age and definition of resolution, although the effect in all studies points in the same direction. ^3^Three studies have high risk of selection bias, including one that is quasi‐randomized, and three did not perform adequate blinding of participants. ^4^High heterogeneity (I^2^ = 81%), although the effect in all studies points in the same direction. ^5^High heterogeneity (I^2^ = 97%), although all effects point in the same direction. ^6^Two of the three studies are classified as quasi‐randomized with inadequate blinding of participants. ^7^A wide CI that does not exclude the threshold of appreciable clinical benefit. ^8^One quasi‐randomized study was not pooled because the authors reported stool output as stool weight in total grams per day with an effect estimate favouring smectite (mean of 255.67 g in the smectite group versus 741.33 g in the control group) at day 3 of treatment. ^9^Wide CI that does not exclude an appreciable benefit or harm.

[^3]: WHO: World Health Organization
